Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
January 28, 2015
Phase 3 Trial of Epilepsy Drug for Cognitive Impairment To Be Initiated
The Alzheimer’s Drug Discovery Foundation has awarded a $900,000 grant to AgeneBio to support the initiation of a Phase 3 clinical trial for AGB101. AGB101 is an investigational therapeutic treatment foramnestic mild cognitive impairment (aMCI).
